Literature DB >> 8331362

Exertional rhabdomyolysis in a patient with calcium adenosine triphosphatase deficiency.

P J Poels1, R A Wevers, J P Braakhekke, A A Benders, J H Veerkamp, E M Joosten.   

Abstract

A patient with exertional rhabdomyolysis and continuously elevated serum creatine kinase (CK) was investigated. The known causes of recurrent attacks of rhabdomyolysis were ruled out by appropriate histochemical and biochemical investigations. During ischaemic exercise tests an abnormal K(+)-efflux from exercising muscles was observed. The patient was found to have a deficiency of muscular Ca(2+)-ATPase. Dantrolene sodium therapy gave relief of muscle symptoms and improved the exercise tolerance. Both the CK level and the K(+)-efflux in ischaemic forearm testing became normal on this therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8331362      PMCID: PMC1015068          DOI: 10.1136/jnnp.56.7.823

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

1.  Microdetermination of (-)carnitine and carnitine acetyltransferase activity.

Authors:  R Parvin; S V Pande
Journal:  Anal Biochem       Date:  1977-05-01       Impact factor: 3.365

Review 2.  Disorders of the mitochondrial respiratory chain: clinical manifestations and diagnostic approach.

Authors:  J M Trijbels; R C Sengers; W Ruitenbeek; J C Fischer; J A Bakkeren; A J Janssen
Journal:  Eur J Pediatr       Date:  1988-11       Impact factor: 3.183

Review 3.  Role of exercise-induced potassium fluxes underlying muscle fatigue: a brief review.

Authors:  G Sjøgaard
Journal:  Can J Physiol Pharmacol       Date:  1991-02       Impact factor: 2.273

4.  Muscle contracture induced by exercise. A syndrome attributable to decreased relaxing factor.

Authors:  I A Brody
Journal:  N Engl J Med       Date:  1969-07-24       Impact factor: 91.245

5.  Beneficial effects of dantrolene sodium in exercise-induced muscle pains: calcium mediated?

Authors:  T Bertorini; G Palmieri; S Bhattacharya
Journal:  Lancet       Date:  1982-03-13       Impact factor: 79.321

6.  (Na+ + K+)-ATPase activity of crude homogenates of rat skeletal muscle as estimated from their K+-dependent 3-O-methylfluorescein phosphatase activity.

Authors:  A Nørgaard; K Kjeldsen; O Hansen
Journal:  Biochim Biophys Acta       Date:  1984-03-14

7.  Carnitine palmitoyltransferase II deficiency with normal carnitine palmitoyltransferase I in skeletal muscle and leucocytes.

Authors:  H R Scholte; F G Jennekens; J J Bouvy
Journal:  J Neurol Sci       Date:  1979-01       Impact factor: 3.181

8.  Prevention of recurrent exertional rhabdomyolysis by dantrolene sodium.

Authors:  P J Haverkort-Poels; E M Joosten; W Ruitenbeek
Journal:  Muscle Nerve       Date:  1987-01       Impact factor: 3.217

9.  Ca2+-ATPase deficiency in a patient with an exertional muscle pain syndrome.

Authors:  D J Taylor; M J Brosnan; D L Arnold; P J Bore; P Styles; J Walton; G K Radda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-11       Impact factor: 10.154

10.  Myopathy caused by a deficiency of Ca2+-adenosine triphosphatase in sarcoplasmic reticulum (Brody's disease).

Authors:  G Karpati; J Charuk; S Carpenter; C Jablecki; P Holland
Journal:  Ann Neurol       Date:  1986-07       Impact factor: 10.422

View more
  3 in total

Review 1.  Mechanism-based therapeutic approaches to rhabdomyolysis-induced renal failure.

Authors:  Olivier Boutaud; L Jackson Roberts
Journal:  Free Radic Biol Med       Date:  2010-10-27       Impact factor: 7.376

2.  Ca2+ homeostasis in Brody's disease. A study in skeletal muscle and cultured muscle cells and the effects of dantrolene an verapamil.

Authors:  A A Benders; J H Veerkamp; A Oosterhof; P J Jongen; R J Bindels; L M Smit; H F Busch; R A Wevers
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

3.  Elevated myoplasmic calcium in exercise-induced equine rhabdomyolysis.

Authors:  J R López; N Linares; G Cordovez; A Terzic
Journal:  Pflugers Arch       Date:  1995-06       Impact factor: 3.657

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.